Levetiracetam add-on for drug-resistant focal epilepsy: an updated Cochrane Review-Reference-Cited by-同舟云学术

Levetiracetam add-on for drug-resistant focal epilepsy: an updated Cochrane Review

Published:2012-09-12 Issue: Volume: Page:
ISSN:1465-1858
Container-title:Cochrane Database of Systematic Reviews
language:en
Short-container-title:

Author:

Mbizvo Gashirai K¹,Dixon Pete²,Hutton Jane L³,Marson Anthony G⁴

Affiliation:

1. University of Liverpool; Institute for Ageing and Chronic Disease; Clinical Sciences Building for Research and Education Lower Lane Liverpool Merseyside UK L9 7LJ

2. University of Liverpool; Molecular and Clinical Pharmacology; Clinical Sciences Building for Research and Education Lower Lane Liverpool Merseyside UK L9 7LJ

3. University of Warwick; Department of Statistics; Coventry UK CV4 7AL

4. Institute of Translational Medicine, University of Liverpool; Department of Molecular and Clinical Pharmacology; Clinical Sciences Centre for Research and Education, Lower Lane Fazakerley Liverpool Merseyside UK L9 7LJ

Publisher

Wiley

Subject

Pharmacology (medical)

Link

http://onlinelibrary.wiley.com/wol1/doi/10.1002/14651858.CD001901.pub2/fullpdf

Reference59 articles.

1. Efficacy and tolerability of levetiracetam 3000 mg/d in patients with refractory seizures: a multicenter, double-blind, responder-selected study evaluating monotherapy. European Levetiracetam Study Group;Ben-Menachem;Epilepsia,2000

2. UCB Evaluation of the efficacy and tolerability of UCB L059 (1500 mg b.i.d., 500 mg tablets) monotherapy in epileptic patients with complex partial onset seizures, having experienced improved seizure control under add-on treatment: a 60-week (maximum), double-blind, multicenter, responder-selected trial (phase III study, placebo comparator) UCB S.A. Pharma Sector

3. A multicentre, double-blind, randomized, parallel group study to evaluate the tolerability and efficacy of two oral doses of levetiracetam, 2000 mg daily and 4000 mg daily, without titration in patients with refractory epilepsy;Betts;Seizure,2000

4. UCB A 24-week multicentered, double-blind, parallel group, add-on study to compare the efficacy and the tolerability of 2 oral daily doses of UCB L059 (2000 mg and 4000 mg tablets) with placebo in patients with refractory epilepsy, followed by a 24-week open-label active treatment UCB S.A. Pharma Sector

5. Levetiracetam for partial seizures: results of a double-blind, randomized clinical trial;Cereghino;Neurology,2000

Cited by 75 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Four Cases of Suspected Levetiracetam-Induced Asymptomatic Rhabdomyolysis;Cureus;2023-07-10

2. Are AI language models such as ChatGPT ready to improve the care of individuals with epilepsy?;Epilepsia;2023-03-13

3. Disease-modifying effects of sodium selenate in a model of drug-resistant, temporal lobe epilepsy;eLife;2023-03-09

4. Optimal regimen of levetiracetam for prevention of busulfan-induced seizure in patients undergoing hematopoietic stem cell transplantation: A review of available evidence;Journal of Oncology Pharmacy Practice;2023-02-27

5. Levetiracetam in the prophylactic treatment of episodic migraine: A prospective open label study;Cephalalgia;2022-05-27